Subscribe To
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter – – Dr. Anne Borgman joined Sutro as Chief Medical Officer in February 2023 – – Sutro expanded its relationship with Vaxcyte through an option agreement for the development and manufacturing rights […] The post Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones appeared first on ForexTV...
Read More
Content Topics
Sutro
Biopharma
Reports
Full
Year
2022
Financial
Results
Results
Business
Highlights
Select
Anticipated
Milestones
Forex
Posted: Mar 30 2023, 20:30
Author Name: forextv
Views: 082164